Sunitinib Malate
2 NDCs across 1 manufacturer|0 Generic,2 Brand
Sunitinib Malate is used to treat renal cell carcinoma, gastrointestinal stromal tumors, neuroendocrine tumors and pancreatic neoplasms, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Jan 26, 2006, and the first generic was approved Aug 16, 2021. FDA's Orange Book lists 36 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $48 million on Sunitinib Malate across 7,751 claims for 1,448 beneficiaries.
Sunitinib Malate is available as 2 NDCs from 1 manufacturer (0 generic, 2 brand), with NADAC prices from $222.41 to $449.06 per EA — the most expensive product costs about 2.0× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
2
0G / 2B
Manufacturers
1
competing in market
Price Spread
$222.41 – $449.06
per EA
7d Activity
avg +0.0% WoW · of 2 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Pfizer Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Kinase Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing SUNITINIB MALATE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
SUTENT 25 MG CAPSULE | $449.0639 per EA | — |
SUTENT 12.5 MG CAPSULE | $222.4063 per EA | — |
Frequently Asked Questions
What is Sunitinib Malate used to treat?
Sunitinib Malate is used to treat renal cell carcinoma, gastrointestinal stromal tumors, neuroendocrine tumors and pancreatic neoplasms, per the National Library of Medicine's MED-RT classification.
When did Sunitinib Malate become available as a generic?
FDA approved the first generic Sunitinib Malate (ANDA) on Aug 16, 2021. The Orange Book currently lists 36 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Sunitinib Malate?
In 2024, Medicare Part D spent $48 million on Sunitinib Malate across 7,751 claims for 1,448 beneficiaries.
How many Sunitinib Malate products are on the market?
The Sunitinib Malate drug market contains 2 NDCs from 1 manufacturer — 0 generic and 2 brand products.
What is the price range for Sunitinib Malate?
NADAC reference prices for Sunitinib Malate range from $222.4063 to $449.0639 per EA — the most expensive product costs about 2.0× the cheapest.
Which manufacturers make Sunitinib Malate?
1 manufacturer lists Sunitinib Malate in NADAC. Ranked by number of NDCs, the largest are Pfizer Inc. (2).